Nightstar Files SEC Paperwork for Initial Public Offering

September 1, 2017: By Jon Swedien

Nightstar TherapeuticsNightstar Therapeutics Limited has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering in the US of its American depositary shares (ADSs) representing ordinary shares, the company announced Aug. 31.

Nightstar is a clinical-stage gene therapy company focused on novel one-time treatments for patients with rare inherited retinal diseases that would otherwise progress to blindness.

All shares to be sold in the offering will be offered by Nightstar, the company said.

The number of shares and price range have not been set, Nightstar said.

The company has applied to list its shares on the NASDAQ Global Market under the ticker symbol “NITE.”

Nightstar expects its lead product candidate, NSR-REP1, to begin a Phase III trial for choroideremia in the the first half of 2018.

The company also has an ongoing Phase I/II clinical trial for NSR-RPGR, a proposed treatment for X-linked retinitis pigmentosa.

In addition, Nightstar has a Phase I/II clinical trial planned for late 2018 for a gene therapy candidate for an inherited form of macular dystrophy.

In June, Nightstar raised $45 million in a Series C financing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023